cvd

Dr. Dapo lluyomade * I think erectile dysfunction, we should really begin to think of erectile dysfunction as subclinical atherosclerosis until proven otherwise Is your patient’s sexual dysfunction an early indicator of serious cardiovascular disease? In this episode of BackTable Urology...

Strength/limitations (see following post)! https://www.emjreviews.com/en-us/amj/cardiology/news/researchers-reveal-the-alarming-long-term-risks-of-steroid-use/ A LONG-TERM study conducted in Denmark has revealed that male users of anabolic androgenic steroids (AAS) face significantly...

* Interpretation of the TRAVERSE findings is limited by several factors. Over 60 % of participants discontinued treatment prior to trial completion, resulting in a median exposure of less than 22 months. Additionally, outcome data were only available for approximately 80 % of the potential...

* PDE5 meds MAY reduce MI, Stroke & Mortality Take Homes for Your Practice from Princeton 4: ED, CVD, and Sexual Function - Martin Miner, MD and Noel N. Kim, PhD Members of the Princeton 4 Commitee

https://www.urologytimes.com/view/pearls-perspectives-helen-bernie-do-mph-at-aua-2025 In this episode of Pearls and Perspectives from Urology Times, host Amy Pearlman, MD, sits down with Helen Bernie, DO, MPH, at the American Urological Association's (AUA) 2025 Annual Meeting in Las Vegas for...

Mohit Khera, MD, MBA, MPH, Professor of Urology and F. Brantley Scott Chair of Urology, Baylor College of Medicine, Houston, Texas, discusses evolving understanding of testosterone therapy and cardiovascular risk. In this 13-minute presentation, Dr. Khera focuses on the pivotal TRAVERSE trial...

Key Takeaways The TRAVERSE trial showed testosterone therapy's MACE risk is non-inferior to placebo, reassuring prescribers and patients. Despite the updated labeling, caution is advised due to potential venous thromboembolic events, particularly pulmonary embolism. Experts anticipate guideline...

* Labs collected include total testosterone (TT), free testosterone (fT), estradiol (E2), hematocrit (Hct), hemoglobin (Hg), triglycerides (TG), total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL). Labs were collected before 11am, fasting, using LCMS and...

* Our findings suggest that mood improvements following TTh initiation may occur progressively, with the most substantial reductions in depressive symptoms observed after 18 weeks post-TTh initiation. TIMING OF MOOD IMPROVEMENT POST TESTOSTERONE THERAPY INITIATION Christian Corsini*, Edoardo...

https://www.vumedi.com/video/hormonal-therapy-and-thrombosis-risk-with-testosterone/

Briefing Document: Optimizing Hematocrit Control in Testosterone Therapy Source: Excerpts from "From Phlebotomy to Formulation: Optimizing Hematocrit Control in Testosterone Therapy - Excel Male TRT Forum" 1. Executive Summary Testosterone Replacement Therapy (TRT) offers significant benefits...

This is key here! * "This now clarifies and substantiates the fact that there are not increased risks from a cardiovascular standpoint with [testosterone] therapy, at least at the doses studied," says Landon Trost, MD...

https://www.urologytimes.com/view/helen-l-bernie-do-mph-on-the-fda-s-labeling-changes-for-testosterone-products "I'm so excited about them finally removing this boxed warning," says Helen L. Bernie, DO, MPH. The FDA’s recent announcement of class-wide labeling changes for testosterone...

* He added, “It is my hope that the AUA will, in short order, go back and change that statement, so that we now have guideline-based instructions to physicians that will say, you are now allowed to say to patients that testosterone therapy is not associated with major adverse cardiovascular...

ABSTRACT Aims The cardiovascular risks associated with anabolic-androgenic steroid (AAS) use, particularly nandrolone decanoate (ND), remain a topic of debate due to conflicting evidence from different types of studies. While observational research frequently reports adverse cardiac effects...

* It is important to note that long-term studies including TRAVERSE, T4DM, and T-Trials have not demonstrated blood pressure increases at periods of one year or greater. The Androgen Society acknowledges that these findings warrant careful consideration in the implementation of blood...

https://www.globenewswire.com/news-release/2025/03/03/3035638/0/en/Marius-Pharmaceuticals-Helps-Drive-FDA-s-Landmark-Testosterone-Label-Update-Removing-Black-Box-Warning.html RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, is pleased to announce that the U.S. Food and...

Abstract Tadalafil is a phosphodiesterase inhibitor currently approved for use in erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). While tadalafil’s benefits in ED and BPH have been well-established for years, its benefits in PAH were...

https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-class-wide-labeling-changes-testosterone-products [2/28/2025] Today, FDA informed sponsors of testosterone products about new labeling changes following the agency’s review of the findings from the Testosterone Replacement...

Fig 1: Change in hematocrit at 12, 48, 72 and 96 months in men receiving testosterone therapy vs. untreated men.5 * Hematocrit levels show significant increase (+4% at month 96) in men receiving TTh. This increase occurred during the first 48 months, as illustrated in figure 1. Final...

Table 1 Guidelines for testosterone therapy in men with prostate cancer Current Evidence and International Medical Organisation’s Guidelines As shown, the guidelines pertaining to testosterone therapy use in hypogonadal men with treated or untreated prostate cancer is shown in Table 1...

In this informative video, Dr. James Simon, a renowned expert in women's health, discusses significant advancements in menopause management as of 2024. He highlights four notable publications from 2024 that delve into the latest research on menopause, providing valuable insights for both...

Dr. Abid Husain is an established cardiologist in the conventional healthcare system. Over the years, while treating patients in a traditional hospital setting, he realized the limitations of this system firsthand. Because of this, he began seeking a way to provide highly impactful, preventative...

Abstract Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine...

In this episode, Dr. Brandon & Dr. Morgentaler discuss how Tadalafil (Cialis) improves heart health, reduces cardiovascular risks, and offers benefits for sexual and overall wellness in both men and women. Chapters: 00:11 Study Overview: Tadalafil and Cardiovascular Risks The hosts...

* Although these epidemiologic data do not prove a causal relationship, they remind us that sex steroid hormones have complex actions and interactions in human health. https://www.acpjournals.org/doi/10.7326/M24-0875 Bradley D. Anawalt, MD University of Washington School of Medicine...

Fig. 1 Proposed mechanism of testosterone and HIV on the systemic vasculature. This figure exemplifies the similarities of both TD and HIV on the vascular system and therefore the potential to enhance CVD risk. Both conditions lead to vessel injury and endothelial dysfunction, which increase...

*Budoff urged clinicians to prioritize bone density screening for postmenopausal women and men over 65, using existing CT imaging when DEXA scans are unavailable. By recognizing the dual risk of cardiovascular disease and osteoporosis, Budoff suggested healthcare providers can implement earlier...

* Lp(a), a low-density lipoprotein (LDL)-like particle with an apo(a) attached to apoB molecule, is now recognized as a potent genetic risk factor, with levels above 50 mg/dL (125 nmol/L) linked to cardiovascular complications, including myocardial infarction, stroke, aortic stenosis...

* he confirms the irrefutable relationship between erectile disfunction (ED) and cardiovascular disease. * Dr. Kohler notes onset of erectile dysfunction can be predictive of myocardial infarction by 2 to 5 years. * Dr. Kohler also presents straightforward algorithms to help determine the...